Pharmacological alternatives to blood transfusion: What is new about?;Alternativas farmacológicas a la transfusión sanguínea. ¿Qué hay de nuevo?

Medicina Clinica

Volumn 122, Issue 6, 2004, Pages 231-236

  Páramo, José A ^a   Lecumberri, Ramón ^a   Hernández, Milagros ^a   Rocha, Eduardo ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Antifibrinolytics; Bood transfusion; Erythropoietin; Factor VIIa; Vasopressin

Indexed keywords

ANTIFIBRINOLYTIC AGENT; APROTININ; ARGIPRESSIN DERIVATIVE; DESMOPRESSIN; ERYTHROPOIETIN; LYSINE DERIVATIVE; PROTEINASE INHIBITOR; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

BLEEDING; BLOOD TRANSFUSION; CANCER; CRITICAL ILLNESS; DRUG EFFICACY; HEART SURGERY; HEMOPHILIA; HUMAN; LIVER SURGERY; ORTHOPEDIC SURGERY; POSTOPERATIVE CARE; REVIEW; SURGICAL PATIENT; THROMBOCYTE ANOMALY; THROMBOCYTE FUNCTION; THROMBOCYTOPENIA; TREATMENT INDICATION;

EID: 12144286624     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13058184     Document Type: Review

References (41)

1. Fillinger M, Surgenor S, Clark C, Hatman G, Paganelli W. The impact of mortality of managing hemodilutional anemia with RBC transfusion after CABG. Anesthesiology 2001;95:A201.
2. Royston D, Nadal A, Dietrich W, Fith J, Levy J, Spiess B. Aprotinin use and adverse outcomes associated with platelet administration. Anesth Analg 2000;90:SCA19.
3. Kovesi T, Royston D. Pharmacological approaches to reducing allogenic blood exposure. Vox Sanguinis 2003;84:2-10.
4. Royston D, Bidstrup BP, Taylor KM, Sapsford RN. Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet 1987;2:1289-91.
5. Rocha E, Páramo JA, Hermida J, Aprotinina en el control de las hemorragias de cirugía. Med Clin (Barc) 1996;106:307-16.
6. Rocha E, Hidalgo F, Llorens R, Melero JM, Arroyo JL, Páramo JA. Randomized study of aprotinin and DDAVP to reduce postoperative bleeding after cardiopulmonary bypass surgery. Circulation 1994;90:921-7.
7. Laupacis A, Fergusson D. Drugs to minimize perioperative blood loss in cardiac surgery: meta-analyses using perioperative blood transfusion as the outcome. The International Study of perio-operative. Transfusion (ISPOT) Investigators. Anesth Analg 1997;85:1258-67.
8. Henry DA, Moxey AJ, Carless PA, O'Connell D, McClellaud B, Henderson KM, et al. Anti-fibrinolytic use for minimising perioperative allogenic blood transfusion. Cochrane Database Syst Rev 2001;1:CD001886.
9. Rosengart TK, Helm RE, DeBois WJ, García N, Krieger KH, Isom OW. Open heart operations without transfusion using multimodality blood conservating strategy in 50 Jehova's Witness patients: implications for a «bloodless» surgical technique. J Am Coll Surg 1997;184:618-29.
10. Levi M, Cromheecke ME, De Jonge E, Prins MH, De Mol BJ, Briet E, et al. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. Lancet 1999;354:1940-7.
11. Porte RJ, Molenar IQ, Begliomini G, Groenland TH, Jamskiewicz A, Lindgren L, et al. Aprotinin and transfusion requirements in orthotopic liver transplantation: a multicentre randomized double-blind study. EMSALT Study Group. Lancet 2000;355:1303-9.
12. Suárez M, Sangro B, Herrero JI, Picardi A, Páramo JA, Quiroga J, et al. Effectiveness of aprotinin in orthotopic liver transplantation. Sem Thromb Haemost 1993;19:292-6.
13. Capdevila X, Calvet Y, Biboulet P, Biron C, Rubenovitch J, d'Athis F. Aprotinin decreases blood loss and homologus transfusion in patients undergoing major orthopedic surgery. Anesthesiology 1998;88:50-7.
14. Boylan JF, Klinck JR, Sandler AN, Arellano R, Greig PD, Nierenberg H, et al. Tranexamic acid reduces blood loss, transfusion requirements, and coagulation factor use in primary orthotopic liver transplantation. Anesthesiology 1996;85:1043-8.
15. Dalmau A, Saate A, Acosta F, García-Huete L, Koo M, Sausano T, et al. Tanexamic acid reduces red cell transfusion better than epsilon-aminocaproic acid or placebo in liver transplantation. Anesth Analg 2000;91:29-34.
16. Engel JM, Hohaus T, Ruwoldt R, Menges T, Jurgensen I, Hempelmann G. Regional haemostatic status and blood requirements after total knee arthroplasty with and without tranexamic acid or aprotinin. Anesth Analg 2001;92:775-80.
17. Neilpovitz DT, Murto K, Hall L, Barrowman NJ, Splinter WW. A randomized trial of tranexamic acid to reduce blood transfusion for scoliosis surgery. Anesth Analg 2001;93:82-7.
18. Mannucci PM. Haemostatic drugs. N Engl J Med 1998;339:245-53.
19. Rocha E, Llorens R, Páramo JA, Arcas R, Cuesta B, Martín Trenor A. Does desmopressin acetate reduce blood loss after surgery in patients after cardiopulmonary bypass? Circulation 1988;77:1319-23.
20. Sheridan DP, Card RT, Pinilla JC, Harding SM, Thomson DJ, Gauthier L, et al. Use of desmopressin acetate to reduce blood transfusion requirements during cardiac surgery in patients with acetylsalicylic-acid-induced platelet dysfunction. Can J Surg 1994;37:33-6.
21. Hedner U, Kisiel W. The use of human factor Vlla in the treatment of two hemophilia patients with high-titer inhibitors. J Clin Invest 1983;71:1836-41.
22. Hedner U, Erhardtsen E. Potential role of rFVlla in transfusion medicine. Transfusion 2002;42:114-24.
23. Lindley CM, Sawyer MT, Macik BG, Lusher J, Harrison JF, Baird-Cox K, et al. Pharmacokinetics and pharmacodynamics of recombinant factor Vlla. Clin Pharmacol Ther 1994;55:638-48.
24. Hedner U. Novoseven as a universal haemostatic agent. Blood Coag Fibrynolysis 2000;11:S107-S11.
25. Kristensen J, Killander A, Hippe E, Helleberg C, Ellegard J, Holm M. Clinical experience with recombinant factor Vlla in patients with thrombocytopenia. Haemostasis 1996;26(Suppl 1):159-64.
26. Poon MC, D'Oiron R. Recombinant activated factor VII (Novoseven) treatment of platelet-related bleeding disorders. International Registry on Recombinant Factor Vlla and congenital platelet disorders. Blood Coag Fibrinolysis 2000;11:S55-S68.
27. Deveras RAE, Dessler CM. Reversal of warfarin-induced excessive anticoagulation with recombinant human factor Vlla concentrate. Ann Intern Med 2002;137:844-8.
28. Kenet G, Walden R, Eldad A, Martinowitz U. Treatment of traumatic bleeding with recombinant factor Vlla. Lancet 1999;354:1879.
29. Martinowitz U, Kenet G, Segal E. Recombinant activated factor VII for adjunctive hemorrhage control in trauma. J Trauma 2001;51:431-8.
30. Friederich PW, Henny CP, Messelink EJ. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial. Lancet 2003;361:201-5.
31. Bernstein DE, Jeffers L, Erhardtsen E, Reddy KR, Glazer S, Squiban P, et al. Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: a preliminary study. Gastroenterology 1997;113:1930-7.
32. Bernstein D. Effectiveness of the recombinant factor Vlla in patients with the coagulopathy of advanced Child's B and C cirrhosis. Sem Thromb Hemost 2000;4:437-8.
33. Hendriks HGD, Meijer K, De Wolf JTM, Klompmaker IJ, Porte RJ, De Kamp PJ, et al. Reduced transfusion requirements by recombinant factor VIIa in orthotopic liver transplantation: A pilot study. Transplantation 2001;71:402-5.
34. Dietrich W, Sapth P, Zuhlsdort M, Dalichan H, Korchhoff PG, Kuppoe H, et al. Anaphylactic reactions to aprotinin re-exposure in cardiac surgery: relation to antiaprotinin immunoglobulin G and E antibodies. Anesthesiology 2001;95:64-71.
35. Hardy JF. Pharmacological strategies for blood conservation in cardiac surgery: erythropoietin and antifibrinolytics. Can J Anaesth 2001;48 (Suppl 4):24-31.
36. Yazicioglu L, Eryilmaz S, Sirlak M, Inan MB, Aral A, Tasoz R, et al. Recombinant human erythropoietin administration in cardiac surgery. J Thorac Cardiovasc Surg 2001;122:741-5.
37. Coyle D, Lee KM, Fergusson DA, Laupacis A. Cost effectiveness of epoietin-alpha to augment preoperative autologous blood donation in elective cardiac surgery. Pharmacoeconomics 2000;18:161-71.
38. Bezwada HP, Nazarian DG, Henry DH, Booth RE Jr. Preoperative use of recombinant human erythropoietin before total joint arthroplasty. J Bone Joint Surg Am 2003;85-A:1795-800.
39. Hebert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G, et al, for the Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trial Group. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. N Engl J Med 1999;340:409-17.
40. Corwin HL, Gettinger A, Peart RG, Fink MP, Levy MM, Shapiro MJ, et al, for the EPO critical Care Trials Group. Efficacy of recombinant human erythropoietin in critically ill patients. JAMA 2002;228:2827-35.
41. Carson JL. Should patients in intensive care units receive erythropoietin? JAMA 2002;288:2884-6.